MRNA - CIK 0001682852
Moderna, Inc. trades as MRNA and has a market capitalization of $18.25 B, making it the #650 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.94B, down 39.9% from the prior year and net income of -$2.82B. This page tracks Moderna, Inc. through 1,447 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Moderna, Inc.'s revenue grew from $108.40M to $1.94B, a compound annual growth rate of 37.8%. Net profit margin expanded from -199.5% to -145.2% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-21 |
| Insider trade | 4 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-15 |
| Major company event | 8-K | 2026-05-11 |
| Insider sale notice | 144 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
May 1, 2026. Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates. Reports first quarter revenue of $0.4 billion, ...
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52). Reiterates 2025 expected revenue ...
The Company anticipates returning to organic sales growth in 2025 and expects to break even in 2026 through product launches and disciplined ...
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billion; Spikevax U.S. market share to date ...
Moderna now projects $1.5 billion to 2.5 billion in revenue in 2025, mostly in the second half of the year, primarily due to Spikevax and ...
The largest companies sharing Moderna, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Moderna, Inc. (MRNA) has a market capitalization of $18.25 B as of 2026-06-10, ranking #650 among US-listed companies.
Moderna, Inc. reported revenue of $1.94B for fiscal year 2025, a decrease of 39.9% year over year.
In its latest fiscal year Moderna, Inc. reported a net loss of $2.82B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.